FGFR1 and cancer: Combining FGFR1 inhibitors with other therapies, such as immune checkpoint inhibitors, PROTAC-based drugs, targeted agents, or chemotherapy, could simultaneously address multiple pathways involved in cancer progression and resistance, enhancing therapeutic effects while reducing doses and associated toxicity.